Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with forearm vasodilator responses in humans

Hypertension

Volumn 57, Issue 1, 2011, Pages 116-122

  Lee, Craig R ^a   Pretorius, Mias ^c   Schuck, Robert N ^a   Burch, Lauranell H ^b   Bartlett, Jackie ^d   Williams, Scott M ^d   Zeldin, Darryl C ^b   Brown, Nancy J ^e  

^a University of North Carolina   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c Center for Human Genetics Research   (United States)

^d Division of Clinical Care Research   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bradykinin; endothelium derived factors; EPHX2 polymorphism; Soluble epoxide hydrolase

Indexed keywords

ARGININE; BRADYKININ; BRADYKININ RECEPTOR; EPOXIDE HYDROLASE; METHACHOLINE; NITROPRUSSIDE SODIUM;

ADULT; ALLELE; ARTERIAL PRESSURE; ARTICLE; BLOOD FLOW; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CONTRAST; ENDOTHELIUM; EUROPEAN AMERICAN; FEMALE; FOREARM; FOREARM BLOOD FLOW; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MALE; MEAN ARTERIAL PRESSURE; PLETHYSMOGRAPHY; PRIORITY JOURNAL; REGULATORY MECHANISM; STATISTICAL SIGNIFICANCE; STRAIN GAUGE TRANSDUCER; VASCULAR RESISTANCE; VASODILATATION; VEIN OCCLUSION; VEIN OCCLUSION PLETHYSMOGRAPHY; VOLUNTEER; WILD TYPE;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; BRADYKININ; COHORT STUDIES; EPOXIDE HYDROLASES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOREARM; GENETIC VARIATION; HUMANS; MALE; METHACHOLINE CHLORIDE; NITROPRUSSIDE; SMOKING; VASCULAR RESISTANCE; VASODILATION; VASODILATOR AGENTS; YOUNG ADULT;

EID: 78650810635     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.161695     Document Type: Article

References (28)

1. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem. 2001;276:36059-36062.
2. Campbell WB, Falck JR. Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors. Hypertension. 2007;49:590-596.
3. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res. 1996;78:415-423.
4. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov. 2009;8:794-805.
5. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension. 2002;39:690-694.
6. Larsen BT, Miura H, Hatoum OA, Campbell WB, Hammock BD, Zeldin DC, Falck JR, Gutterman DD. Epoxyeicosatrienoic and dihydroxyeico-satrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol. 2006;290:H491-H499.
7. Theken KN, Lee CR. Genetic variation in the cytochrome P450 epoxy-genase pathway and cardiovascular disease risk. Pharmacogenomics. 2007;8:1369-1383.
8. Zhang L, Ding H, Yan J, Hui R, Wang W, Kissling GE, Zeldin DC, Wang DW. Genetic variation in cytochrome P450 2J2 and soluble epoxide hydrolase and risk of ischemic stroke in a Chinese population. Pharma-cogenet Genomics. 2008;18:45-51.
9. Fornage M, Boerwinkle E, Doris PA, Jacobs D, Liu K, Wong ND. Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation. 2004;109:335-339.
10. Gschwendtner A, Ripke S, Freilinger T, Lichtner P, Muller-Myhsok B, Wichmann HE, Meitinger T, Dichgans M. Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with an increased risk of is-chemic stroke in white Europeans. Stroke. 2008;39:1593-1596.
11. Lee CR, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, Hammock BD, Couper DJ, Heiss G, Zeldin DC. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet. 2006;15:1640-1649.
12. Fava C, Montagnana M, Danese E, Almgren P, Hedblad B, Engstrom G, Berglund G, Minuz P, Melander O. Homozygosity for the EPHX2 K55R polymorphism increases the long-term risk of ischemic stroke in men: a study in Swedes. Pharmacogenet Genomics. 2010;20:94-103.
13. Fornage M, Lee CR, Doris PA, Bray MS, Heiss G, Zeldin DC, Boer-winkle E. The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. Hum Mol Genet. 2005;14:2829-2837.
14. Przybyla-Zawislak BD, Srivastava PK, Vazquez-Matias J, Mohrenweiser HW, Maxwell JE, Hammock BD, Bradbury JA, Enayetallah AE, Zeldin DC, Grant DF. Polymorphisms in human soluble epoxide hydrolase. Mol Pharmacol. 2003;64:482-490.
15. Koerner IP, Jacks R, DeBarber AE, Koop D, Mao P, Grant DF, Alkayed NJ. Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury. J Neurosci. 2007;27: 4642-4649.
16. Merkel MJ, Liu L, Cao Z, Packwood W, Young J, Alkayed NJ, Van Winkle DM. Inhibition of soluble epoxide hydrolase preserves cardio-myocytes: role of STAT3 signaling. Am J Physiol Heart Circ Physiol. 2010;298:H679-H687.
17. Lee J, Dahl M, Grande P, Tybjaerg-Hansen A, Nordestgaard BG. Genetically reduced soluble epoxide hydrolase activity and risk of stroke and other cardiovascular disease. Stroke. 2010;41:27-33.
18. Pretorius MM, Gainer JV, Van Guilder GP, Coelho EB, Luther JM, Fong P, Rosenbaum DD, Malave HA, Yu C, Ritchie MD, Vaughan DE, Brown NJ. The bradykinin type 2 receptor BE1 polymorphism and ethnicity influence systolic blood pressure and vascular resistance. Clin Pharmacol Ther. 2008;83:122-129.
19. Van Guilder GP, Pretorius M, Luther JM, Byrd JB, Hill K, Gainer JV, Brown NJ. Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition. Hypertension. 2008;51:454-459.
20. Brown NJ, Gainer JV, Murphey LJ, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclo-oxygenase-independent pathway. Circulation. 2000;102:2190-2196.
21. Rosenbaum DA, Pretorius M, Gainer JV, Byrne D, Murphey LJ, Painter CA, Vaughan DE, Brown NJ. Ethnicity affects vasodilation, but not endothelial tissue plasminogen activator release, in response to bra-dykinin. Arterioscler Thromb Vasc Biol. 2002;22:1023-1028.
22. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA. 2003;100:9440-9445.
23. Ohtoshi K, Kaneto H, Node K, Nakamura Y, Shiraiwa T, Matsuhisa M, Yamasaki Y. Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients. Biochem Biophys Res Commun. 2005;331:347-350.
24. Revermann M, Schloss M, Barbosa-Sicard E, Mieth A, Liebner S, Morisseau C, Geisslinger G, Schermuly RT, Fleming I, Hammock BD, Brandes RP. Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice. Arterioscler Thromb Vasc Biol. 2010;30:909-914.
25. Simpkins AN, Rudic RD, Roy S, Tsai HJ, Hammock BD, Imig JD. Soluble epoxide hydrolase inhibition modulates vascular remodeling. Am J Physiol Heart Circ Physiol. 2010;298:H795-H806.
26. Srivastava PK, Sharma VK, Kalonia DS, Grant DF. Polymorphisms in human soluble epoxide hydrolase: effects on enzyme activity, enzyme stability, and quaternary structure. Arch Biochem Biophys. 2004;427: 164-169.
27. Enayetallah AE, Grant DF. Effects of human soluble epoxide hydrolase polymorphisms on isoprenoid phosphate hydrolysis. Biochem Biophys Res Commun. 2006;341:254-260.
28. Smith NL, Hindorff LA, Heckbert SR, Lemaitre RN, Marciante KD, Rice K, Lumley T, Bis JC, Wiggins KL, Rosendaal FR, Psaty BM. Association of genetic variations with nonfatal venous thrombosis in postmenopausal women. JAMA. 2007;297:489-498.